Mindspace by Numinus is pleased to be at the forefront of psychedelic-assisted psychotherapy solutions in Canada. Specifically, in light of Health Canada’s revision to its Special Access Program, our medical team is now able to submit applications on behalf of appropriate candidates for potential treatment with psilocybin and MDMA. In order to be considered for a SAP application, you must meet the following criteria:

  • A diagnosis of treatment-resistant depression or Post Traumatic Stress Disorder (PTSD) that is currently assessed to be “serious or life-threatening“.
  • Previous attempts at conventional treatment that “have failed, are unsuitable or are unavailable“.

Numinus intends to offer the option for SAP applications to other mental health conditions in the future. You may therefore select some currently unavailable conditions below, and will be contacted in the future when they are offered.

Think psychedelic-assisted psychotherapy through the SAP application process could be for you? Complete the form below to get started.

  • What is Psychedelic-Assisted Psychotherapy with MDMA and psilocybin?

    MDMA and psilocybin are two psychedelics that are currently being studied and in the process of being approved in Canada and the United States for the treatment of a number of indications including PTSD, depression, anxiety, and substance use disorders.

    Though they are not fully approved yet for treatment, Health Canada has recently issued a statement with the intent of revising the Special Access Programme, which allows individuals to access other regulated substances for the treatment of various health issues if other means have failed. We are in the process of collecting the information of potential candidates for applications for these treatments, should the revision to the SAP go through in early 2021.

  • What is Psychedelic-Assisted Psychotherapy?

    Psychedelic assisted-psychotherapy (PAP) is a form of psychotherapy that involves the use of psychedelic substances such as psilocybin, MDMA and ketamine for the purpose of facilitating therapeutic breakthroughs and insight.

    It is a broad term that encompasses a number of different approaches and protocols using psychedelics, and which has been practiced in the Western medical model since the 1950s. Though psychedelics like LSD showed promise as therapeutic agents in those early years, a period of prohibition starting in the 1960s and through the early 2000s significantly hindered the research and development of these modalities.

    The last decade has seen a significant body of encouraging research supporting the efficacy of PAP for a number of mental health issues, especially depression, anxiety, addiction, and PTSD. Though most psychedelics are still regulated substances, the legal and medical landscape is changing quickly, and more treatment options are starting to become available to the general public.

From the Blog